Recent advances in the treatment of epithelial ovarian cancer

Bibliography

• HOWE HL, WINGO PA, THUN MJ et al.: Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. I Natl. Cancer Inst. (2001) 93:824–842.
   PubMed Web of Science ®Google Scholar
• AABO K, ADAMS M, ADNITT P et al.: Chemotherapy in advanced ovarian cancer: four systematic meta-analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists Group. Br. J. Cancer. (1998) 78:1479–1487.
   PubMed Web of Science ®Google Scholar
• KAYE SB: Intravenous chemotherapy for ovarian cancer - the state of the art? Irm Cyrrecol. Cancer (2000) 10:19–25.
   Web of Science ®Google Scholar
• TRIMBLE EL, ADAMS JD, VENA D et al.: Paclitaxel for platinum-refractory ovarian cancer: results from the first 1,000 patients registered to National Cancer Institute Treatment Referral Center 9103. _J. CM]. Oricol. (1993) 11:2405–2410.
   PubMed Web of Science ®Google Scholar
• THIGPEN JT, BLESSING JA, BALL H, HUMMEL SJ, BARRETT RJ: Phase II trial of paclitaxel in patients with progressive ovarian carcinoma after platinum-based chemotherapy: a Gynecologic Oncology Group study. I OM. Oricol. (1994) 12:1748–1753.
   PubMed Web of Science ®Google Scholar
• MCGUIRE WP ROWINSKY EK, ROSENSHEIN NB et al.: Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. Intern. Med. (1989) 111:273–279.
   PubMed Web of Science ®Google Scholar
• KOHN EC, SAROSY G, BICHER A et al.:Dose-intense taxol: high response rate in patients with platinum-resistant recurrent ovarian cancer. j Natl. Cancer Inst. (1994) 86:18–24.
   PubMed Web of Science ®Google Scholar
• EINZIG Al, WIERNIK PH, SASLOFF J, RUNOWICZ CD, GOLDBERG GL: Phase II study and long-term follow-up of patients treated with taxol for advanced ovarian adenocarcinoma. Oricol.(1992) 10:1748–1753.
   PubMed Web of Science ®Google Scholar
• MCGUIRE WP, HOSKINS WJ, BRADY MF et al.: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl. j Med. (1996) 334:1–6.
   PubMed Web of Science ®Google Scholar
• ••These studies provide rationale for the useof paclitaxel in first-line regimens.
   Google Scholar
• PICCART MJ, BERTELSEN K, JAMES K etal.: Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results. Natl. Cancer Inst. (2000) 92:699–708.
   Google Scholar
• ••These studies provide rationale for the useof paclitaxel in first-line regimens. OZOLS RF, BUNDY BN, FOWLER J et al.: Randomized Phase III Study of Cisplatin (CIS)/Paclitaxel (PAC) Versus Carboplatin (CARBO)/PAC in Optimal Stage III Epithelial Ovarian Cancer (OC): A Gynecologic Oncology Group Trial (GOG 158). Proceedings of Proceedings of the American Society of Clinical Oncology (1999):1373
   Google Scholar
• DU BOIS A, NEIJT JP, THIGPEN JT: First line chemotherapy with carboplatin plus paclitaxel in advanced ovarian cancer--a new standard of care? Ann. Oricol. (1999) 10:35–41.
   Google Scholar
• NEIJT JP, ENGELHOLM SA, TUXEN MK et al.: Exploratory Phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. Oricol. (2000) 18: 3084–3092.
   PubMed Web of Science ®Google Scholar
• COLOMBO N: Randomised trial of paclitaxel (PTX) and carboplatin (CBDCA) versus a control arm of carboplatin or CAP (cyclophosphamide, doxorubicin & cisplatin): The Third International Collaborative Ovarian Neoplasm Study (ICONS). Proceedings of ASCO. (2000):1500.
   Google Scholar
• MUGGIA FM, BRALY PS, BRADY MF et al.: Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. j Chi]. arca (2000) 18:106–115.
   Google Scholar
• KAERN J, TROPE CG, BAEKELANDT M, KRISTENSEN GB: Phase II trial of weekly single agent paclitaxel (P) in platinum (PLAT) and paclitaxel refractory ovarian cancer (OC). Proceedings of ASCO. (2001):810.
   Google Scholar
• ANDERSSON H, BOMAN K, RIDDERHEIM M etal.: An updated analysis of a randomized study of single agent paclitaxel (P) given weekly versus every 3 weeks to patients (Pts) with ovarian cancer (OV) treated with prior platinum therapy. Proceedings of ASCO. (2000):1505.
   Google Scholar
• BERTELSEN K, JAKOBSEN A, STROYER J et al.: A prospective randomized comparison of 6 and 12 cycles of cyclophosphamide, adriamycin, and cisplatin in advanced epithelial ovarian cancer: a Danish Ovarian Study Group trial (DACOVA). Cynecol Oncol (1993) 49:30–36.
   PubMed Web of Science ®Google Scholar
• HAKES TB, CHALAS E, HOSKINS WJ etal.: Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Cynecol Oncol (1992) 45:284–289.
   Google Scholar
• BELOTTI D, VERGANI V, DRUDIS T et al.: The microtubule-affecting drug paclitaxel has antiangiogenic activity. Clin. Cancer Res. (1996) 2:1843–1849.
   PubMed Web of Science ®Google Scholar
• DU BOIS A, WEBER B, PFISTERER J et al.: Epirubicin/paclitaxel/carboplatin (TEC) vs. pacliaxel/carboplatin (TC) in first-line treatment of ovarian cancer FIGO stages JIB-TV Interim results of an ago-gineco intergroup Phase III trial. Proceedings of ASCO. (2000:805.
   Google Scholar
• KAYE SB, PICCART M, AAPRO M, FRANCIS P AND KAVANAGH J: Phase II trials of docetaxel (Taxotere) in advanced ovarian cancer--an updated overview. Eur. Cancer (1997) 33:2167–2170.
   PubMed Web of Science ®Google Scholar
• BISSERY MC, NOHYNEK G, SANDERINK GJ, LAVELLE F: Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. Anticancer Drugs (1995) 6:339-355, 363–338.
   Google Scholar
• VERSCHRAEGEN CE SITTISOMWONG T, KUDELKA AP et al.: Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. j. Oncol (2000) 18:2733–2739.
   Google Scholar
• VASEY PA, ATKINSON R, COLEMAN R et al.: Docetaxel-carboplatin as first line chemotherapy for epithelial ovarian cancer. Br. J. Cancer (2001) 84:170–178.
   PubMed Web of Science ®Google Scholar
• VASEY P: Preliminary Results of the SCOTROC II Trial: A Phase III comparison of paclitaxel-carboplatin (PC) and docetaxel-carboplatin (DC) as first-line chemotherapy for stage Ic-IV epithelial ovarian cancer (EOC). Proceedings of ASCO. (2000804.
   Google Scholar
• •A large randomised study demonstrating equivalent efficacy of docetaxel and paclitaxel in first-line regimens.
   Google Scholar
• CREEMERS GJ, BOLIS G, GORE M et al.: Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European Phase II study. Oncol (1996) 14:3056–3061.
   Google Scholar
• TEN BOKKEL HUININK W, GORE M, CARMICHAEL J etal.: Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer. j. Clin. Oncol (1997) 15:2183–2193.
   Google Scholar
• BOOKMAN MA, MALMSTROM H, BOLIS G et al: Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label Phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel.j Clin Oncol. (1998) 16:3345–3352.
   PubMed Web of Science ®Google Scholar
• HOSKINS P, EISENHAUER E, BEARE S etal.: Randomized Phase II study of two schedules of topotecan in previously treated patients with ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group study. j. Clin. Oncol (1998) 16:2233–2237.
   Google Scholar
• MARKMAN M, KENNEDY A, WEBSTER K etal.: Phase 2 evaluation of topotecan administered on a 3-day schedule in the treatment of platinum- and paclitaxel-refractory ovarian cancer. Cynecol. Oncol. (2000) 79:116–119.
   Google Scholar
• BROWN JV, 3RD, PETERS WA, 3RD, RETTENMAIER MA et al.: A Phase I trial of a 3-day topotecan Q 21 days for recurrent epithelial cancers of the ovary, fallopian tube, and peritoneum. Cynecol Oncol. (2000) 79:495–498.
   Google Scholar
• BOS AME, DE VRIES EGE, VAN DER ZEE AGL et al: Phase land pharmacokinetic study of intraperitoneal topotecan. Proceedings of ASCO. (1999):1404.
   Google Scholar
• CLARKE-PEARSON DL, VAN LE L, IVESON T et al.: A Phase II study of oral topotecan as a single agent, second line therapy, administered for five days in patients with advanced ovarian cancer. Proceedings of ASCO. (1999):1421.
   Google Scholar
• MUGGIA FM, HAINSWORTH JD, JEFFERS S etal.: Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation. j. Oncol (1997) 15:987–993.
   Google Scholar
• GORDON AN, GRANAI CO, ROSE PG etal.: Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. j. Oncol (2000) 18:3093–3100.
   Google Scholar
• ISRAEL VP, GARCIA AA, ROMAN L et al.: Phase II study of liposomal doxorubicin in advanced gynecologic cancers. Cynecol Oncol (2000) 78:143–147.
   PubMed Web of Science ®Google Scholar
• MARKMAN M, KENNEDY A, WEBSTER K et al.: Phase 2 trial of liposomal doxorubicin (40 mg/m(2)) in platinum/paclitaxel-refractory ovarian and fallopian tube cancers and primary carcinoma of the peritoneum. Cynecol Oncol (2000) 78:369–372.
   PubMed Web of Science ®Google Scholar
• SAFRA T, GROSHEN S, JEFFERS S et al: Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin. Cancer (2001) 91:90–100.
   PubMed Web of Science ®Google Scholar
• GORDON AN, FLEAGLE JT, GUTHRIE D et al.: Interim analysis of a Phase III randomized trial of Doxil/Caelyx (D) versus Topotecan (T) in the treatment of patients with relapsed ovarian cancer. Proceedings of ASCO. (2000):1504.
   Google Scholar
• •A randomised study comparing topotecan and caelyx in relapsed EOC.
   Google Scholar
• ROSE PG, BLESSING JA, MAYER AR, HOMESLEY HD: Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J. Clin. Onca(1998) 16:405–410.
   Web of Science ®Google Scholar
• PELAEZ I, LACAVE AJ, PALACIO I et al:Phase II trial of epirubicin at standard dose in relapsed ovarian cancer. Eur. j. Cancer (1996) 32A:899–900.
   PubMed Web of Science ®Google Scholar
• COLEMAN R, TOWLSON K, WILTSHAW E et al: Epirubicin for pretreated advanced ovarian cancer. Eur. Cancer (1990) 26:850–851.
   PubMed Web of Science ®Google Scholar
• VERMORKEN JB, TEN BOKKEL HUININK WW, KOBIERSKA A et al.: Phase I study of high-dose epirubicin in platinum-pretreated patients with ovarian carcinoma. Oncology (1999) 57:10–16.
   Google Scholar
• VERMORKEN JB, KOBIERSKA A, CHEVALLIER B et al.: A Phase II study of high-dose epirubicin in ovarian cancer patients previously treated with cisplatin. EORTC Gynecological Cancer Cooperative Group. Ann. Oncol (2000) 11:1035–1040.
   Google Scholar
• VERMORKEN JB, KOBIERSKA A, VAN DER BURG ME et al.: High-dose epirubicin in platinum-pretreated patients with ovarian carcinoma: the EORTC-GCCG experience. Eur. I Cynaecol. Oncol (1995) 16:433–438.
   Google Scholar
• LUND B, HANSEN OP, THEILADE K, HANSEN M, NEIJT JP: Phase II study of gemcitabine (2, 2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. J. Nat/. Cancer Inst. (1994) 86:1530–1533.
   PubMed Web of Science ®Google Scholar
• LUND B, HANSEN OP, NEIJT JP, THEILADE K AND HANSEN M: Phase II study of gemcitabine in previously platinum-treated ovarian cancer patients. Anticancer Drugs (1995) 6(Suppl 6):61–62.
   PubMedGoogle Scholar
• FRIEDLANDER M, MILLWARD MJ, BELL D et al.: A Phase II study of gemcitabine in platinum pre-treated patients with advanced epithelial ovarian cancer. Ann. Oricol. (1998) 9:1343–1345.
   PubMed Web of Science ®Google Scholar
• SHAPIRO JD, MILLWARD MJ, RISCHIN D et al.: Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. Cyrtecol. Ortcol. (1996) 63:89–93.
   Google Scholar
• VON MINCKWITZ G, BAUKNECHT T, VISSEREN-GRUL CM, NEIJT JP: Phase II study of gemcitabine in ovarian cancer. Ann. Oricol. (1999) 10:853–855.
   PubMed Web of Science ®Google Scholar
• HANSEN SW, ANDERSON H, BOMAN K et al: Gemcitabine, Carboplatin, and Paclitaxel (GCP) as first-line treatment of ovarian cancer FIGO Stages IIB--IV. Proceedings of ASCO. (1999) 1379
   Google Scholar
• HAUGE MD, LONG HJ, HARTMANN LC et al: Phase II trial of intravenous hexamethylmelamine in patients with advanced ovarian cancer. Invest. New Dugs (1992) 10:299–301.
   PubMed Web of Science ®Google Scholar
• MANETTA A, TEWARI K AND PODCZASKI ES: Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature. Cyrtecol. arca (1997) 66:20–26.
   Google Scholar
• MARKMAN M, BLESSING JA, MOORE D, BALL H, LENTZ SS: Altretamine (hexamethylmelamine) in platinum-resistant and platinum-refractory ovarian cancer: a Gynecologic Oncology Group Phase II trial. Cyriecol Oricol (1998) 69:226–229.
   Google Scholar
• ROSEN GF, LURAIN JR AND NEWTON M: Hexamethylmelamine in ovarian cancer after failure of cisplatin-based multiple-agent chemotherapy. Cyriecol. Oricol (1987) 27:173–179.
   Google Scholar
• STEHMAN FB, EHRLICH CE, CALLANGAN MF: Failure of hexamethylmelamine as salvage therapy in ovarian epithelial adenocarcinoma resistant to combination chemotherapy. Cyriecol Oricol (1984) 17:189–195.
   Google Scholar
• MANETTA A, MACNEILL C, LYTER JAet al.: Hexamethylmelamine as a single second-line agent in ovarian cancer. Cyriecol Oricol (1990) 36:93–96.
   Google Scholar
• MOORE DH, VALEA E CRUMPLER LS, FOWLER WC, JR.: Hexamethylmelamine/ altretamine as second-line therapy for epithelial ovarian carcinoma. Cyriecol Oricol (1993) 51:109–112.
   Google Scholar
• CHOLLET P, BENSMAINE MA, BRIENZA S et al: Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann. Oricol (1996) 7:1065–1070.
   PubMed Web of Science ®Google Scholar
• PICCART MJ, GREEN JA, LACAVE AJ et al.: Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: A randomized Phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. Oricol(2000) 18:1193–1202.
   PubMed Web of Science ®Google Scholar
• SOULIE P, BENSMAINE A, GARRINO C et al.: Oxaliplatin/cisplatin (L-OHP/ CDDP) combination in heavily pretreated ovarian cancer. Eur. j Cancer (1997) 33:1400–1406.
   PubMed Web of Science ®Google Scholar
• SORENSEN P, HOYER M, JAKOBSEN A et al: Phase II study of vinorelbine in the treatment of platinum-resistant ovarian carcinoma. Cyriecol Oricol. (2001) 81:58–62.
   Google Scholar
• BAJETTA E, DI LEO A, BIGANZOLI L et al.: Phase II study of vinorelbine in patients with pretreated advanced ovarian cancer: activity in platinum-resistant disease. Oricol (1996) 14:2546–2551.
   PubMed Web of Science ®Google Scholar
• GERSHENSON DM, BURKE TW, MORRIS M et al.: A Phase I study of a daily x3 schedule of intravenous vinorelbine for refractory epithelial ovarian cancer. Cyriecol Oricol (1998) 70:404–409.
   Google Scholar
• NARDI M, DE MARCO S, FABI A et al: Ifosfamide and vinorelbine in advanced pretreated ovarian cancer: a Phase II study. Cancer Chemother. Pharmacol . (2000) 45:513–515.
   PubMed Web of Science ®Google Scholar
• BURGER RA, DISAIA PJ, ROBERTS JA et al: Phase II trial of vinorelbine in recurrent and progressive epithelial ovarian cancer. Cyriecol. Oricol (1999) 72:148–153.
   Google Scholar
• WEBB A, AHERN R, EVERARD M et al.: High activity of epirubicin, cisplatin, protracted venous infusional (PVI) 5-fluorouracil (ECF) after platinum and taxanes in relapsed epithelial ovarian cancer (ROC). Proceedings of ASCO (2000):1566.
   Google Scholar
• HAY MP: ZD-0473 AstraZeneca. Curl: Opirt. Investig. Drugs (2000) 1:263–266.
   Google Scholar
• GORE M, ATKINSON RJ, DIRIX L et al: ZD0473 Phase II monotherapy trial in second-line ovarian cancer. Proceedings of ASCO. (2000:2501.
   Google Scholar
• SESSA C, CAPRI G, GIANNI L etal.: Clinical and pharmacological Phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. Ann. Oricol (2000) 11:977–983.
   Google Scholar
• CALVERT H, SESSA C, CARMICHAEL Jetal.: An intermittent Phase I and pharmacokinetic study of BBR3464, a novel cationic triplatinum complex. Proceedings of 25th ESMO congress. (2000):604.
   Google Scholar
• WOLFF AC, BAKER SD, BOWLING MK etal.: Phase I study of taxoprexin DHA-paclitaxel (TXP), a novel taxane with unique preclinical activity, toxicity profile and pharmacology Proceedings of NCI-EORTC-AACR Symposium on New Drugs irt Cancer Therapy Amsterdam (2000):570.
   Google Scholar
• HIDALGO M, AYLESWORTH C, HAMMOND LA et al: Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. j OM. Oricol (2001) 19:2493–2503.
   PubMed Web of Science ®Google Scholar
• EMERSON DL, BENDELE R, BROWN E et al.: Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan. Chit. Cancer Res. (2000) 6:2903–2912.
   PubMed Web of Science ®Google Scholar
• CALVERT PM, O'NEILL V, TWELVES C etal.: A Phase I clinical and pharmacokinetic study of EP0906 (epothilone 13), given every three weeks, in patients with advanced solid tumours. Proceedings of ASCO. (2000:429.
   Google Scholar
• SPRIGGS D, SOIGNET S, BIENVENU B etal.: Phase I first-in-man study of epothilone B analog BMS-247550 in patients with advanced cancer. Proceedings of ASCO. (2000:428.
   Google Scholar
• RYAN DP, SUPKO JG, EDER JP et al.: Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. OM. Cancer Res. (2001) 7:231–242.
   Web of Science ®Google Scholar
• TAAMMA A, MISSET JL, RIOFRIO Met al.: Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J. OM. Oricol. (2001) 19:1256–1265.
   Google Scholar
• DELALOGE S, YOVINE A, TAAMMA A et al.: Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients--preliminary evidence of activity. Oricol. (2001) 19:1248–1255.
   PubMed Web of Science ®Google Scholar
• VASEY E MCMAHON L, PAUL J, KAYE S: A Phase II trial of capecitabine in relapsed ovarian cancer. Proceedings of ESMO 25 (2000)373.
   Google Scholar
• NICULESCU-DUVAZ I: ZD-9331 AstraZeneca. Corr. Opin. Investig. Drugs (2000) 1:141–149.
   PubMedGoogle Scholar
• ALBERTS DS, LIU PY, HANNIGAN EV et al.: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl. I Med. (1996) 335:1950–1955.
   PubMed Web of Science ®Google Scholar
• MARKMAN M AND OZOLS RF: Intraperitoneal chemotherapy. In: Ovarian Cancer: Controversies in Management.Gershenson DM and McGuire WP (Ed). Churchill Livingstone, (1998)343–357.
   Google Scholar
• HATCH KD, BEECHAM JB, BLESSING JA, CREASMAN WT: Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer (1991) 68:269–271.
   Google Scholar
• •Reports on the efficacy of tamoxifen in relapsed EOC.
   Google Scholar
• MARKMAN M, ISEMINGER KA, HATCH KD et al.: Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Cynecol. Oricol. (1996) 62:4–6.
   PubMed Web of Science ®Google Scholar
• •Reports on the efficacy of tamoxifen in relapsed EOC.
   Google Scholar
• MELLINGHOFF IK AND SAWYERS CL: Kinase inhibitor therapy in cancer. In: Cancer. Principles, and Practice of Oncology,DeVita VT, Hellman S, and Rosenberg SA (Eds). Lippincott Williams and Wilkins, (2000) PPO UPDATE 12/00.
   Google Scholar
• CIARDIELLO F, CAPUTO R, BIANCO R et al.: Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin. Cancer Res. (2000) 6:2053–2063.
   PubMed Web of Science ®Google Scholar
• FINKLER N, GORDON A, CROZIER M etal.: Phase 2 evaluation of OSI-774 a potent oral antagonist of the EGFR-TK in patients with advanced ovarian carcinoma. Proceedings of ASCO. (2001):831
   Google Scholar
• HELLSTROM I, GOODMAN G, PULLMAN J, YANG Y, HELLSTROM KE: Overexpression of HER-2 in ovarian carcinomas. Cancer Res. (2001) 61:2420–2423.
   PubMed Web of Science ®Google Scholar
• RYAN PD, CHABNER BA: On receptor inhibitors and chemotherapy. Clin. Cancer Res. (2000) 6:4607–4609.
   PubMed Web of Science ®Google Scholar
• HIRTE HW, VERGOTE IB, JEFFREY JR, GRIMSHAW RN, AL E: An international muticentre III study of BAY 12-9566 versus placebo in patients with advanced ovarian cancer responsive to primary surgery/ paclitaxel + platinum containing chemotherapy. Proceedings of ASCO. (2001):843.
   Google Scholar
• IOANNIDES CG, FISK B, JEROME KR etal.: Cytotoxic T cells from ovarian malignant tumors can recognize polymorphic epithelial mucin core peptides. bronuriol. (1993) 151:3693–3703.
   Google Scholar
• FISK B, BLEVINS TL, WHARTON JT, IOANNIDES CG: Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J. Exp. Med. (1995) 181:2109–2117.
   PubMed Web of Science ®Google Scholar
• GONG J, NIKRUI N, CHEN D et al.: Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. I bronuriol. (2000) 165:1705–1711.
   Google Scholar
• WEN SF, MAHAVNI V, QUIJANO E et al.: Evidence of p53 gene transfer and its biological activities in ovarian cancer patients receiving multiple cycles of recombinant adenovirus expressing wild-type p53. Proceedings of ASCO. (2001):849.
   Google Scholar
• VASEY PA, SEIDEN M, O'NEILL VO et al.: Phase I trial of intra peritoneal Onyx-015 in patients with recurrent ovarian cancer. Proceedings of ASCO. (2000):1512
   Google Scholar
• FRACASSO PM, BRADY MF, MOORE DH etal.: Phase II study of paclitaxel and valspodar (PSC 833) in refractory ovarian carcinoma: a gynecologic oncology group study. J. Clin. Oricol. (2001) 19:2975–2982.
   Google Scholar
• BAEKELANDT M, LEHNE G, TROPE CG et al.: Phase I/II trial of the multidrug-resistance modulator valspodar combined with cisplatin and doxorubicin in refractory ovarian cancer. j. Clin. Oricol. (2001) 19:2983–2993.
   PubMed Web of Science ®Google Scholar
• FIELDS A, HOCHSTER H, RUNOWICZ C et al.: P5C833: initial clinical results in refractory ovarian cancer patients. Corr. Opin. Oricol. (1998) 10\(Suppl. 1): S21.
   Google Scholar